|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GIP analogues augment bone strength by modulating bone composition in diet-induced obesity in mice.
|
31765668 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GIP also enhances long-chain triglyceride (LCT) diet-induced obesity and insulin resistance.
|
30990747 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) is closely related to diabetes and obesity, both of which are confirmed to increase the risk of coronary artery disease (CAD).
|
29765988 |
2018 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Among the gastrointestinal hormones, the incretins: glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 have attracted interest because of their importance for the development and therapy of type 2 diabetes and obesity.
|
31815785 |
2020 |
|
Obesity
|
0.300 |
GeneticVariation
|
disease |
BEFREE |
In humans, genomewide association studies have identified single nucleotide polymorphisms (SNPs) in the GIPR gene that are strongly associated with body mass index (BMI); however, it is not clear whether genetic variations in the GIP gene are involved in the development of obesity.
|
25324507 |
2014 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) receptor (GIPR) is associated with obesity in human genome-wide association studies (GWAS).
|
31511854 |
2020 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide [also known as gastric inhibitory polypeptide (GIP)] and its receptor (GIPR) may link overnutrition to obesity, insulin resistance, and type 2 diabetes.
|
22237064 |
2012 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
The effect of GIP on obesity measures was substantially different between men and women.
|
26505824 |
2016 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Loss or attenuation of GIP receptor (GIPR) action leads to resistance to diet-induced obesity through incompletely understood mechanisms.
|
31451430 |
2019 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide (GIP) was recently linked to adipocyte metabolism and obesity-related metabolic disorders, including NAFLD, induced by an excess of saturated fatty acids (SFAs), but its role in vivo, as well as underlying mechanisms, is unknown.
|
19141695 |
2009 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Glucose-dependent insulinotropic polypeptide is secreted after food consumption and gipr knockout mice fed a high-fat diet are protected against obesity and disturbances in glucose homeostasis.
|
22399504 |
2012 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
Gastric inhibitory polypeptide (GIP) is postulated to be involved in type 2 diabetes mellitus and obesity.
|
19254363 |
2009 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
GLP-1 and GIP combination is suggested as a promising therapeutic strategy for treatment of obesity and diabetes.
|
28610922 |
2017 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
RGD |
In conclusion, both obese and diabetic rats had an impaired early-phase insulinotropic effect of GIP due to impaired gene expression of GIP-Rs which could be a potential target to prevent transition of obesity to diabetes and to improve insulin secretion in the latter.
|
18063845 |
2007 |
|
Obesity
|
0.300 |
Biomarker
|
disease |
BEFREE |
In this study, we assessed the role of GIP in hyperphagia induced obesity and metabolic abnormalities in leptin deficient (Lep<sup>ob/ob</sup>) mice.
|
28271035 |
2017 |